読み込み中
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
前日終値
$0.605
+$0.005 · +0.83%
市場前
$0.6075
+$0.0025 · +0.41%
10月12日 7:52 ET
日中の時刻はETです。市場データは遅延する場合があります。
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
日中レンジ
現在 $0.605
52週レンジ
現在 $0.605
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
51
適正価値
センチメント
69
強気
リスク
45
やや高いリスク
モメンタム
69
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
日中レンジ
現在 $0.605
52週レンジ
現在 $0.605
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.46億 USD | 1.45億 USD | 1.46億 USD | 1.57億 USD | 2.1億 USD |
| 売上原価 | 594.9万 USD | 600.7万 USD | 494.2万 USD | 521.3万 USD | 340.2万 USD |
| 粗利益 | 1.4億 USD | 1.39億 USD | 1.41億 USD | 1.52億 USD | 2.06億 USD |
| 研究開発 | 1.26億 USD | 1.43億 USD | 1.39億 USD | 1.49億 USD | 1.61億 USD |
| 販売・一般管理 | 1.05億 USD | 1.15億 USD | 1.32億 USD | 1.45億 USD | 1.44億 USD |
| 営業費用 | 2.31億 USD | 2.59億 USD | 2.71億 USD | 2.94億 USD | 3.05億 USD |
| 受取利息 | 277.3万 USD | 740万 USD | 1094.3万 USD | 235.9万 USD | 58.2万 USD |
| 支払利息 | 4584.9万 USD | 3742.2万 USD | 2382.3万 USD | 2499.6万 USD | 2604.6万 USD |
| 減価償却費と償却費 | 29.6万 USD | 34万 USD | 53万 USD | 62.1万 USD | 78.9万 USD |
| 営業利益 | −9070.7万 USD | −1.19億 USD | −1.3億 USD | −1.42億 USD | −9827.1万 USD |
| 純利益 | −1.96億 USD | −7642.2万 USD | −1.43億 USD | −1.65億 USD | −1.24億 USD |
会社概要が更新されました 2026年10月12日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$9.50
上昇余地（1470.25%）AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
